Maj-Britt Kaltoft
Corporate Officer/Principal bei Statens Serum Institute
Profil
Maj-Britt Kaltoft is currently the Head of Business Development & Patent Functions at Statens Serum Institute.
She previously worked as an Independent Director at SANUWAVE Health, Inc., Director at Nycomed Hellas SA, Vice President of Corporate Alliance Management at Novo Nordisk A, Principal at H.
Lundbeck A, and Chief Operating Officer at EffRx, Inc. She also held the position of Chief Operating Officer at EffRx Pharmaceuticals SA and Vice President of International Licensing at Takeda A.
Kaltoft received her graduate degree from the University of Copenhagen in 1990 and her doctorate in 1998.
She also received a graduate degree from Seattle University in 1998.
Aktive Positionen von Maj-Britt Kaltoft
Unternehmen | Position | Beginn |
---|---|---|
Statens Serum Institute | Corporate Officer/Principal | 01.01.2017 |
Ehemalige bekannte Positionen von Maj-Britt Kaltoft
Unternehmen | Position | Ende |
---|---|---|
SANUWAVE HEALTH, INC. | Direktor/Vorstandsmitglied | 28.06.2021 |
NOVO NORDISK A/S | Corporate Officer/Principal | 01.01.2016 |
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | Geschäftsführer | 10.06.2011 |
Nycomed Hellas SA | Direktor/Vorstandsmitglied | 01.01.2007 |
H. LUNDBECK A/S | Corporate Officer/Principal | 01.01.2003 |
Ausbildung von Maj-Britt Kaltoft
University of Copenhagen | Doctorate Degree |
Seattle University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 3 |
---|---|
NOVO NORDISK A/S | Health Technology |
H. LUNDBECK A/S | Health Technology |
SANUWAVE HEALTH, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | Health Technology |
Nycomed Hellas SA | |
EffRx Pharmaceuticals SA
EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Health Technology |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |